Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1992 1
1994 2
1995 1
1997 4
1998 2
1999 2
2000 1
2001 5
2002 1
2003 1
2004 2
2005 5
2006 6
2007 4
2008 5
2009 4
2010 3
2011 4
2012 7
2013 5
2014 3
2015 4
2016 7
2017 6
2018 6
2019 1
2020 3
2021 3
2022 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

91 results

Results by year

Filters applied: . Clear all
Page 1
Randomized trial of TAS-102 for refractory metastatic colorectal cancer.
Mayer RJ, Van Cutsem E, Falcone A, Yoshino T, Garcia-Carbonero R, Mizunuma N, Yamazaki K, Shimada Y, Tabernero J, Komatsu Y, Sobrero A, Boucher E, Peeters M, Tran B, Lenz HJ, Zaniboni A, Hochster H, Cleary JM, Prenen H, Benedetti F, Mizuguchi H, Makris L, Ito M, Ohtsu A; RECOURSE Study Group. Mayer RJ, et al. N Engl J Med. 2015 May 14;372(20):1909-19. doi: 10.1056/NEJMoa1414325. N Engl J Med. 2015. PMID: 25970050 Free article. Clinical Trial.
Novel anti-angiogenic therapeutic strategies in colorectal cancer.
Tampellini M, Sonetto C, Scagliotti GV. Tampellini M, et al. Expert Opin Investig Drugs. 2016;25(5):507-20. doi: 10.1517/13543784.2016.1161754. Epub 2016 Mar 24. Expert Opin Investig Drugs. 2016. PMID: 26938715 Free article. Review.
The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials.
Fucà G, Guarini V, Antoniotti C, Morano F, Moretto R, Corallo S, Marmorino F, Lonardi S, Rimassa L, Sartore-Bianchi A, Borelli B, Tampellini M, Bustreo S, Claravezza M, Boccaccino A, Murialdo R, Zaniboni A, Tomasello G, Loupakis F, Adamo V, Tonini G, Cortesi E, de Braud F, Cremolini C, Pietrantonio F. Fucà G, et al. Among authors: tampellini m. Br J Cancer. 2020 Aug;123(3):403-409. doi: 10.1038/s41416-020-0894-7. Epub 2020 May 19. Br J Cancer. 2020. PMID: 32424148 Free PMC article.
Novel investigational therapies for treating biliary tract carcinoma.
Tampellini M, La Salvia A, Scagliotti GV. Tampellini M, et al. Expert Opin Investig Drugs. 2016 Dec;25(12):1423-1436. doi: 10.1080/13543784.2016.1252330. Epub 2016 Nov 3. Expert Opin Investig Drugs. 2016. PMID: 27771967 Free article. Review.
Surrogate Endpoints in Second-Line Trials of Targeted Agents in Metastatic Colorectal Cancer: A Literature-Based Systematic Review and Meta-Analysis.
Cremolini C, Antoniotti C, Pietrantonio F, Berenato R, Tampellini M, Baratelli C, Salvatore L, Marmorino F, Borelli B, Nichetti F, Bironzo P, Sonetto C, Bartolomeo MD, Braud F, Loupakis F, Falcone A, Di Maio M. Cremolini C, et al. Among authors: tampellini m. Cancer Res Treat. 2017 Jul;49(3):834-845. doi: 10.4143/crt.2016.249. Epub 2016 Nov 15. Cancer Res Treat. 2017. PMID: 27857020 Free PMC article. Review.
In reply.
Tampellini M, Ardissone F, Scagliotti GV. Tampellini M, et al. Oncologist. 2013;18(5):638. doi: 10.1634/theoncologist.2013-0034. Epub 2013 Apr 26. Oncologist. 2013. PMID: 23624498 Free PMC article.
91 results